LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

Author's Avatar
Dec 14, 2022

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test’s ongoing development and future launch into developing countries